ABT Abbott Laboratories
Legal ·
Abbott Laboratories, a defendant in numerous NEC lawsuits, agreed to resolve the Gill case, where a jury awarded $495 million, and claims for about 2,000 other infants. About 1,700 lawsuits remain pending.
Abbott agreed on November 20, 2025 to buy Exact Sciences for $105 per share in cash, an equity value the companies put at about $21 billion. Abbott's commitment letter provides up to $20 billion of bridge loans, and the companies expect the deal to close in the second quarter of 2026, subject to a shareholder vote and antitrust review.
Abbott Laboratories is an Illinois corporation whose principal business is the discovery, development, manufacture and sale of a broad and diversified line of healthcare products. It reports four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Medical Devices. The Established Pharmaceutical Products segment sells branded generic medicines, mainly outside the United States in emerging markets, across gastroenterology, women's health, cardiovascular and metabolic, pain and central nervous system, and respiratory products, including biosimilars. The Diagnostic Products segment offers laboratory, molecular and point-of-care systems and tests for areas such as cancer, cardiac and metabolic disorders, infectious diseases and drugs of abuse, including the Alinity family of instruments. The Nutritional Products segment sells infant formula such as Similac and adult and pediatric nutrition products such as Ensure, Glucerna and PediaSure. On November 19, 2025, Abbott agreed to acquire Exact Sciences Corporation, which is expected to enable Abbott to enter the cancer diagnostics market. The deal is subject to customary closing conditions, including approval by Exact Sciences shareholders and required regulatory clearances.
| Product or program | What it is | Stage |
|---|---|---|
| Creon | Treats pancreatic exocrine insufficiency from cystic fibrosis and chronic pancreatitis | |
| Alinity family of instruments | Core laboratory and molecular diagnostic systems | |
| Similac infant formula | Pediatric infant and follow-on formula products | |
| Ensure | Adult nutritional products |
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | $44.33 billion | $41.95 billion |
| Research and development | $2.94 billion | $2.84 billion |
| Net income (loss) | $6.52 billion | $13.40 billion |
| Cash from operations | $9.57 billion | $8.56 billion |
| Cash and equivalents | $8.52 billion | $7.62 billion |
| Short-term investments | $417.0 million | $351.0 million |
Our latest story on this, dated Nov 20, 2025: "Abbott agrees to acquire Exact Sciences for $105 per share in cash, about $21 billion". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Aug 20, 2026: "Abbott agrees to settle Gill case and preterm formula NEC claims for approximately $670 million". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Aug 20, 2026: "Abbott agrees to settle Gill case and preterm formula NEC claims for approximately $670 million". The story links the filing or release it is based on. Read the story.
Abbott Laboratories trades under the ticker ABT on NYSE.
Abbott Laboratories is listed on NYSE.
The SEC Central Index Key (CIK) for Abbott Laboratories is 1800. Its filings are on SEC EDGAR.
Our directory records Abbott Laboratories under United States.
Our directory classifies Abbott Laboratories as: Diversified pharmaceuticals/medtech. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Abbott Laboratories is US0028241000.
aibio.space lists Abbott Laboratories among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as IL.
Abbott Laboratories is an Illinois corporation whose principal business is the discovery, development, manufacture and sale of a broad and diversified line of healthcare products. It reports four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Medical Devices.
Creon: Treats pancreatic exocrine insufficiency from cystic fibrosis and chronic pancreatitis
Alinity family of instruments: Core laboratory and molecular diagnostic systems
$44.33 billion for the fiscal year ended Dec 31, 2025, as reported to the SEC.
Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 8-K (Items 8.01,9.01). Source
Reported a merger or acquisition agreement. SEC Form 8-K (Items 8.01,9.01). Source
Filed a final prospectus for a securities offering. SEC Form 424B5. Source
Reported a merger or acquisition agreement. SEC Form 8-K (Items 1.01,7.01,8.01,9.01). Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio